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Abstract
Background: An altered amniotic cytokine profile has been reported in inflammatory pregnancy complications
with a leading role for IL-6, a marker of the foetal systemic inflammatory response. Up to this date there is no
exhaustive information neither on the foetal cytokine balance nor on the best method for its modulation. We
aimed to evaluate the influence of vaginal lactoferrin administration on amniotic fluid concentration of 47
cytokines, chemokines and growth factors.
Methods: Sixty women undergoing genetic amniocentesis were enrolled in an open-label clinical trial. 300 mg of
vaginal lactoferrin (Florence, Italy) were randomly administered to obtain 3 groups: A, 20 untreated patients; B and
C (20 patients in each) respectively treated 4 and 12 h before amniocentesis. Cytokines, chemokines and growth
factors concentrations were quantified by a magnetic bead Luminex multiplex immunoassays panel technology.
Data analysis was performed with the software Stata (v. 13.1) and GraphPad Prism (v. 5). Group comparisons were
performed using Kruskal–Wallis followed by Mann–Whitney U tests, with Bonferroni correction for multiple
comparisons. A p < 0.05 was considered significant.
Results: Among the 47 tested mediators, 24 (51.06%) were influenced by lactoferrin. 11 (23.4%), showed a highly
significant difference (p <0.001); among these IL-9, IL-15, IFN-γ, IP-10, TNF-α, IL-1α and MCP-3 underwent a
down-regulation, while IL-17 and FGF-basic, G-CSF, GM-CSF an up-regulation. Difference between group C and
both B and A was small for IL-15, IP-10, IL-1α, MCP-3, while it was negligible for IL-9, IFN-γ and TNF-α. IL-17 and
the 3 growth factors were strongly enhanced in B and C groups. IL-17, FGF-basic and GM-CSF showed increasing
concentrations in both B and C groups, while G-CSF resulted up-regulated only in group C. Significance was
intermediate (p < 0.01) for the down regulated IL-2RA, IL-12p40 and IFNα2 (6.38%) while it was small for 10
mediators (21.27%) 7 of which (IL-2, IL-4, eotaxin, PDGF-BB, RANTES, IL-18 and MIF) down-regulated and 3
(MCP-1, IL-3, and SDF-1α) up-regulated.
Conclusion: Lactoferrin down-regulates 17 pro-inflammatory amniotic mediators while up-regulating 7 anti-
inflammatory amniotic mediators, 5 of which definitively belonging to an anti-inflammatory profile. These findings
open to clinical investigation on its use against inflammatory complications of pregnancy.
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Background
Successful pregnancy depends on an orderly production
of trophoblast mediators aimed at modulating maternal
adaptation, progressively increasing uterine-placental per-
fusion to draw substances for foetal growth. This task
must be directly performed by the foetus, counteracting
the natural reaction against the trophoblast induced uter-
ine blood vessel rupture, that in any other tissue but
uterus should activate inflammatory changes leading to
coagulation and smooth muscle contraction. Such a foetal
capacity must be even stronger in the presence of mater-
nal pathologic conditions linked with inflammation, like
rheumatic disease, coagulation, and thrombophilia. With
regard to maternal immunity and related mediators, it has
been reported that Th1-type is incompatible with success-
ful pregnancy, while Th2-type is protective [1].
As for the foetal role, there is a large body of data on
normal trophoblast function [2] as well as evidence indi-
cating that foetal chromosomal abnormalities are charac-
terized by alteration of some mediators of inflammation
and coagulation which may explain the high incidence of
early abortion linked with aneuploidy [3, 4]. Such evidence
reinforces the concept of a direct foetal control on normal
gestational processes.
Furthermore, an altered amniotic cytokine profile has
been reported in pregnancy complications such as pre-
mature delivery and chorioamnionitis with a leading role
for IL-6, a marker of the foetal systemic inflammatory
response [5]. In this regard, once recognized that an in-
creased concentration of IL-6 in the foetal compartment
cannot be considered a benign condition, attempts were
made to reduce it by administering antibiotic [6, 7] as
well as by lactoferrin (LF) administration [8]. Up to this
date there is no exhaustive information neither on the
foetal cytokine balance nor on the best method for its
modulation, when clinically justified. Therefore, with the
aim to contribute to a better understanding of the foetal
mediators of physiological pregnancy, we analysed mid-
trimester amniotic fluid (AF) concentration of a 47 cyto-
kines panel, in basal condition as well as upon assump-
tion of LF, an 80 kDa iron binding glycoprotein of the
transferrin family, component of the mammalian innate
immune system provided with anti-inflammatory and
antimicrobial properties [9].
Methods
We performed an open-label clinical study enrolling 60
pregnant patients undergoing genetic amniocentesis at
the 16th gestational week at the Obstetric Unit of Ferrara
University from March 2011 to March 2012. The inclu-
sion criteria were: singleton physiological pregnancy and
maternal age as the only indication to foetal karyotyping.
The exclusion criteria were: assumption of drugs inter-
fering with the immune system, previous miscarriages,
pregnancy at risk for maternal or foetal disease. The re-
search was carried out in accordance with the ethical
principles of the Declaration of Helsinki. The Local
Ethics Committee approved the design of this study
and all pregnant women gave their written informed
consent. Moreover, a questionnaire was administered to
the patients in order to check for any complications
(vaginal bleeding, uterine contraction, rupture of the
membranes) within 7 days following the procedure.
Our protocol entails using a 22-gauge needle provided
with a 24-gauge tip to reduce the diameter of the hole in
the amniotic membrane and the consequent risk of AF
leakage. Eligible patients were randomly assigned in a
1:1:1 ratio with a random number table to receive a vaginal
compound containing 300 mg of LF (Difesan, Progine,
Italy) to obtain 3 groups:
 group A: 20 untreated patients;
 group B: 20 patients treated 4 h before
amniocentesis;
 group C: 20 patients treated 12 h before
amniocentesis.
Based on a previous study, the compound was admin-
istered in the pharmaceutical form of a tablet by means
of an applicator deeply inserted into the vaginal route.
A total amount of 20 ml AF was withdrawn for karyo-
type analysis, microbiological culture, α-fetoprotein (18 ml)
and cytokines analysis.
Fresh AF specimens (1 ml) were centrifuged at 3000 g,
4 °C for 10 min, aliquoted and stored at −80 ° C until
analysis. In supernatant specimens diluted (1:4) and tested
in triplicate, the chemokines and cytokines concentrations
were quantified by a magnetic bead Luminex multiplex
immunoassays panel technology (47 analytes) (Bio-Plex,
BIORAD Laboratories, Milan, Italy), as previously de-
scribed [10]. The samples were treated following manu-
factures’ instructions, using the Bio-Plex array reader
(Luminex, Austin, TX) to determine the cytokines levels
expressed as concentration (pg/mL) by the Manager
software. The validation of the Bioplex platform has
been performed in our laboratory using the sandwich
ELISA assay as the reference [11].
Data analysis was performed with the software Stata
(v. 13.1) and GraphPad Prism (v. 5). Group comparisons
were performed using Kruskal–Wallis followed by Mann–
Whitney U tests, with Bonferroni correction for multiple
comparisons. A p < 0.05 was considered significant.
Results
The mean maternal age in the whole study population
was 37.5 ± 2.1 years (minimum 35, maximum 42). This
parameter was not different among the 3 groups (p = 0.5)
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and distributed as follows: 37.8 (±2.4), 37.7 (±2.3) and 37.1
(±2.1) years, for groups A, B and C, respectively.
A normal karyotype was registered in all cases. The
AF microbiological cultures were negative in all the
tested samples. No complications were registered within
7 days after amniocentesis, and the course of pregnancy
was normal in all patients, ending in spontaneous deliv-
ery at term. Among the 47 tested mediators, 24 (51.06%)
were influenced by LF administration although with dif-
ferent levels of statistically significant difference. In par-
ticular, 11 (23.4%), showed a highly significant difference
(p <0.001); among these, 7 mediators (IL-9, IL-15, IFN-γ,
IP-10, TNF-α, IL-1α, MCP-3) underwent a down-regulation,
4 (IL-17 and 3 factors FGF-basic growth, G-CSF, GM-CSF)
an up-regulation. The statistical difference between group C
and both B and A was small for IL-15, IP-10, IL-1α, MCP-3,
while it was negligible for IL-9, IFN-γ and TNF-α. (Table 1,
Fig. 1). As for the strongly up-regulated ones, IL-17 and 3
growth factors (FGF-basic, G-CSF, GM-CSF) were enhanced
in groups B and C. In particular IL-17, FGF-basic and
GM-CSF showed increasing concentrations in both
groups B and C, while G-CSF resulted up-regulated in
group C only (Table 1, Fig. 2).
Three of the mediators analysed (6.38%) IL-2RA, IL-
12p40 and IFNα2 were down-regulated and showed an
intermediate statistical significance (p < 0.01).
Finally, 10 mediators (21.27%) were influenced with a
weakly significance (p < 0.05). Among these, 7 (IL-2, IL-4,
eotaxin, PDGF-BB, RANTES, IL-18 and MIF) were down-
regulated and the remaining 3 (MCP-1, IL-3, and SDF-1α)
up-regulated (Table 1).
The analysis by ELISA confirmed the concentration
trend observed with the BIO-plex Luminex XMap analysis.
Although quantitative differences were found between ab-
solute values for the cytokines obtained by Luminex and
ELISA assays are found, the relative values are comparable
and the two methods have shown similar trends, as also
reported in recent literature [12–14].
Table 1 Amniotic fluid concentration of mediators showing statistically significant difference in the three groups of examined patients
Cytokines Group A Group B Group C
Down-regulated IL-9*** 35.69 (33.96–50.89)a,d 5.89 (0.15–14.31) 7.52 (4.61–10.01)
TNF-α*** 61.63 (56.49–72.93)a,d 1.63 (1.63–30.97) 19.99 (1.63–29.06)
IP-10*** 38964 (27318–108516)a,d 7739 (4945–14536) 8732 (5422–12633)
IFN-γ*** 66.84 (51.9–76.64)a,d 24.7 (17.66–44.11) 27.7 (12.88–47.51)
MCP-3*** 174.3 (89.8–216.3)a,d 28.63 (22.13–44.32) 30.49 (23.79–41.70)
IL-15*** 81.27 (0.42–99.4) a,e 0.42 (0.42–0.42) 0.42 (0.42–0.42)
IL-1α*** 7.9 (0.35–11.75)c,d 0.35 (0.35–0.35) 0.35 (0.35–0.35)
IL-2RA** 1659 (771,5–2414)e 800.9 (426.2–3125) 5957 (496.2–854.5)
Il-12p40** 1809 (1170–2518)e 1.17 (1.17–917) 1.17 (1.17–1.17)
IFN-α2** 195.1 (128.9–233.1)c,e 127.3 (103.2–146.8) 120.1 (98.18–135)
IL-2* 30.04 (0.2–35.02)c,f 0.2 (0.2–2.95) 0.2 (0.2–4.1)
IL-4* 1.97 (0.06–2.6)c 0.06 (0.06–1.475) 1.09 (0.06–2.1)
EOTAXIN* 300.4 (11.49–432.1)c,f 6.01 (0.48–23.2) 15.67 (0.48–31.28)
PDGF-BB* 89.13 (53.04–122.1)c 39.86 (30.24–70.64) 50.43 (30.62–95.22)
RANTES* 37.75 (7.07–42.58)c 0.52 (0.52–32.96) 21.37 (0.52–39.84)
Il-18* 240 (82.3–336.6)f 98.97 (47.37–263.3) 67.72 (52.95–164.1)
MIF* 2155 (1587–3005)c 1440 (1063–1804) 1446 (1098–2232)
Up-regulated Il-17*** 37.02 (32.75–45.11)d 0.44 (0.44–205.5) g 302.8 (100–480.6)
FGF-b*** 36.59 (34.57–39.21)d 0.25 (0.25–105.8) g 100 (99–202.2)
G-CSF*** 115.5 (45.26–354)d 162 (43.92–599.8) h 742.1 (362–1943)
GM-CSF*** 231 (201.8–253.8)b 300 (284.2–325.8) 350.5 (300–411.4)
MCP-1* 167.8 (78.68–386–7)f 401.2 (215.6–515.5) 374.6 (258.4–695.2)
IL-3* 404.7 (321.4–483.7)c 537.7 (398.1–697) 537.7 (350.3–612.1)
SDF-1α* 152 (129.8–661.2)f 541 (261.1–703.5) 617 (541.3–711.8)
Data are given as medians (quartiles) (pg/ml); ***p < 0.001; **p < 0.01; *p < 0.05
Group A vs Group B: ap < 0.001; bp < 0.01; cp < 0.05
Group A vs Group C: dp < 0.001; ep < 0.01; fp < 0.05
Group B vs Group C: gp < 0.001; hp < 0.01
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Discussion
Given the key-role of foetal mediators in the regulation
of pregnancy, a better knowledge of their normal profile
and their possible pharmacologic modulation is needed.
As we previously demonstrated that vaginal LF adminis-
tration significantly down-regulates amniotic IL-6 in
women undergoing genetic amniocentesis [8], we found
it noteworthy to extend our observation to other cyto-
kines, chemokines and growth factors in basal condition
as well as upon the action of the glycoprotein.
By analysing our data, 24 out of 47 (51.06%) tested
mediators were significantly influenced by LF. Among the
group with the highest statistical significance (p < 0.001)
comprising of 11 analytes, 7 were down-regulated (IL-9,
IL-15, IFN-γ, IP-10, TNF-α, IL-1α, MCP-3) while the
remaining 4 (IL-17 FGF-basic, G-CSF, GM-CSF) were up-
regulated. Most of the down-regulated ones belong to the
pro-inflammatory type. Although IL-9 is more frequently
associated with allergy, its role in Th1-mediated inflam-
mation has been recently reported. As for IL-15, it is
Fig. 1 Differences among strongly down-regulated mediators in the three groups. Legend: Data are given as medians (quartiles) (pg/ml); ***p < 0.001;
**p < 0.01; *p < 0.05
Fig. 2 Differences among strongly up-regulated mediators in the three groups. Legend: Data are given as medians (quartiles) (pg/ml); ***p < 0.001;
**p < 0.01; *p < 0.05
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present in the amniochorion and decidua, and increased
amniotic concentration was found in preterm labour [15].
Furthermore, the increased amniotic level of the trad-
itional inflammatory cytokines IL-1a, TNF-α, IFN-γ as
well as of IL-1beta, IL-4, IL-6, IL-8 and MCP-1 are be-
lieved to represent a marker for identification of the pa-
tients at risk of preterm delivery [16]. Together with
physiology of gestation, the above mediators also control
foetal health. In fact, it has been reported that an in-
creased level of pro-inflammatory cytokines TNF-α, IL-1,
IL-6, IL-11, as well as VEGF, TGF-α and TGF-β, may
damage the foetal capillary endothelium and alveolar epi-
thelium, resulting in hyaline membrane formation. This
evidence demonstrates that the cause of hyaline mem-
brane disease is not prematurity per se, but rather inflam-
matory conditions leading to both premature delivery and
foetal disease.
Accordingly, the inflammatory role of IL-1 has also
been experimentally documented on sheep by intra-
amniotic injection of the recombinant ovine cytokine,
which induces a strong elevation of the intestinal mRNA
levels for IFN-γ, TNF-α, IL-4 and IL-10. This increased
pro-inflammatory state is associated with a decreased
level of the intestinal fatty acid binding protein, disrup-
tion of the tight junctional protein ZO-1 and loss of
ileum mucosal barrier [17]. Only two chemokines were
found to be strongly down-regulated, namely IP-10 and
MCP-3.
Of note, the mean levels of IP-10 we measured are al-
most 5 times higher than in previous reports [18]. The
observed discrepancy may be due to the different meth-
odology used, since Luminex assay showed higher abso-
lute cytokine values than ELISA, with a good correlation
and a similar trend between the two assays. (12-13-14).
Nevertheless, since IP-10 is a pro-inflammatory chemo-
kine, the high value recovered in the control group (A)
may be related to a physiological response to asymptom-
atic infection, not diagnosed by routine microbiological
culture. In fact, as shown in our study, IP-10 was found
to be strongly down-regulated after LF intake, a glycopro-
tein with anti-inflammatory and antimicrobial properties.
Increased amniotic fluid level of IP-10 has been re-
ported in presence of foetal Down Syndrome, suggesting
a link with the increased abortion rate observed in an-
euploid pregnancy [19]. Accordingly, a possible role in
adverse events of pregnancy, was suggested for other
inflammatory cytokines in foetal aneuploidies [3, 4]. Fi-
nally, high levels of TNF-α and MCP-3 have recently
been observed in AF of women with preterm birth [20].
Such evidence suggests a possible beneficial role for
both chemokines down-regulated by LF.
Among the strongly up-regulated mediators there were
3 growth factors, FGF-basic, G-CSF, GM-CSF and the
cytokine IL-17. The latter belongs to a complex family
including six more members, namely IL-17/IL-17A,
IL-17B, IL-17C, IL-17D, IL-17E/IL-25, produced by
several different cell types and primarily prompting Th2-
and Th9-type responses. Some of these components
activate IL-4, IL-5 and IL-13 expression, as well as eo-
sinophil recruitment. In particular, IL-17 has been
linked to inflammatory conditions of pregnancy such
as chorioamnionitis leading to preterm delivery [21].
Although our data showed an up-regulation of IL-17
12 h after LF intake when compared to the control group
thus suggesting a possible detrimental effect of the treat-
ment, it is noteworthy that at 4 h the difference in the
cytokine level was no longer visible. It should be noted
that the main effects of LF intake, in terms of statistical
significance, are observed at 4 h for most of the tested cy-
tokines, as demonstrated before [8]. Thus, this possible
discrepancy between the results observed at 4 h and at
12 h might be attributable to sampling characteristics.
As for the 3 growth factors evaluated in our study, lit-
tle is known about their behaviour during pregnancy.
FGF-basic, has been reported to stimulate the growth of
cultured amniotic fluid cells, without harmful effects on
chromosomes [22]. GM-CSF is a hematopoietic cytokine
provided with neurotrophic and neuroprotective functions
for which specific pregnancy-stage and organ modulation
have been reported in mice foetuses [23]. Finally, G-CSF
has been reported to improve pregnancy rate, reducing re-
current miscarriage in assisted reproduction [24].
With regard to the group with intermediate statistical
significance, IL-2RA, IL-12p40 and IFN-α2 were all down-
regulated. High levels of the first two are linked with pre-
eclampsia [25] recurrent miscarriage [26] and preterm
birth of growth retarded neonates [27]. Down-regulation
of IFN-α2 may possibly be beneficial considering it be-
longs to the same IFN-γ family. In particular, IFN type I
(IFN-α) promotes the expression of T lymphocyte recep-
tors for IL-12, the primary inducer of TH1 population.
The group which showed the lowest statistical signifi-
cance (p < 0.05), includes 10 mediators, among which 7
down-regulated, namely IL-2, IL-4, IL-18, EOTAXIN,
RANTES, MIF and PDGF-BB, and 3 up-regulated, i.e.
IL-3, SDF-1, MCP-1.
IL-2 and IL-4 belong to the specific immune response
of T lymphocytes to protein antigens. Physiologically,
they regulate lymphocyte differentiation and growth and
activate macrophages and eosinophils, thus producing
local tissue damage such as granulomatous inflammation.
As for their role during pregnancy, only the receptor for
IL-4 (IL-4r), but not the levels of IL-4 and IL-2 have been
reported to increase in pre-eclampsia [28].
IL-18, mainly produced by macrophages, belongs to
the innate immunity, activating NK and T cells, as well
as stimulating IFN-γ production. Its specific function in
pregnancy has not been investigated yet, but considering
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the above-mentioned effects, its decrease following LF
administration may be beneficial.
RANTES and Eotaxin are both produced by Th2, al-
though respectively responsible for inflammation and
allergy. Provided with pro-invasive function, they are
released in the mucosal secretion, needing to be pre-
cisely balanced, as an excessive amount can affect the
outcome of pregnancy [29, 30]. It is therefore worthy of
note that LF is able to reduce their amniotic concentra-
tion. The same appears to be true for the MIF produced
by the trophoblast at the implantation site, and re-
ported to be linked to pre-eclampsia [31].
With regard to PDGF-BB, this factor is included among
the factors regulating the endometrial stromal cell motility
at the implantation site [32]. Down-regulation of this fac-
tor following LF administration needs extensive clinical
investigation.
Among the slightly up-regulated mediators, we found
the last three molecules: IL-3, SDF-1 and MCP-1. The
first one is a haematopoiesis promoting factor, whose ma-
ternal serum level increases as a function of the trimester
[33]; the second compound, SDF-1, is a CXC-chemokine
expressed by human trophoblast, enhancing VEGF release
and possibly facilitating spiral arteries remodelling [34].
The small increase of MCP-1 is more difficult to clas-
sify. As reported above, LF induced a highly significant
down-regulation of the same chemokine family member
MCP-3 and therefore a similar action on MCP-1 was ex-
pected. This may be due to the 2 molecules sharing only
70% of the same structure or the distinct receptor usage
and spectrum of action: MCP-3 binds to CCR1, CCR2,
and CCR3 receptors [33] while MCP-1 binds only CCR2.
Accordingly, MCP-3 only partially overlaps MCP-1 action,
for instance, the first is active on eosinophils and dendritic
cells, which are not affected by MCP-1. Based on such evi-
dence, so far it has not been possible to hypothesize any
clinical implication for the small increase of MCP-1 in
comparison with the strong decrease of MCP-3.
The maternal immune system undergoes a significant
modulation during pregnancy. Historically, it is believed
that such adaptation is needed to induce tolerance to-
wards the foetal antigens derived from the inherited pa-
ternal genome. However, it became clear that the so
called ‘rejection’ of the product of conception does not
derive from an antigen-antibody reaction, but rather, even
simpler, from an inflammatory one. Indeed, successful
pregnancy appears to be assured throughout a delicate
balance of pro- and anti-inflammatory cytokines, chemo-
kines and prostanoids, modulating the maternal response
towards foetal invasion, but preserving at the same time
the capacity to prevent infections from a multitude of po-
tential pathogens. Although maternal mediators shift to-
wards acceptance has not been completely understood, it
is known that an anti-inflammatory profile is essential for
successful pregnancy, while an inflammatory one can lead
to serious complications, including abortion [1], preterm
labour, infection and perinatal death [35].
Modulation of maternal immune system is a task of
the foetus itself.
Such a logical conviction derives not only from the
knowledge of mediators produced by trophoblast [2],
but also from studies indicating that foetal aneuploidy -
which is by definition linked with pregnancy loss - is
characterized by imbalance of cytokines, peptides and
prostanoids known to modulate maternal immune re-
sponse and vascular changes. Indeed, at this regard,
while it is admitted that amniotic fluid cytokines may
also be maternal [36], those produced in vitro by cyto-
trophoblast can only be foetal. They represent the tool
by which the foetus modulates maternal response, and
their imbalance must be considered a feature of the
foetus itself [3, 4, 37, 38].
Conversely, since the maternal reaction can also be in-
fluenced by pre-existing conditions, the outcome of
pregnancy will ultimately depend on the comparison of
the foetal ability with the maternal response.
From an anatomy perspective, it can be accepted that
vaginally administered LF is absorbed to enter the ma-
ternal circulation and it is then transferred to the foetal
compartment through the placental barrier, like any
other glycoprotein such as maternal antibodies. Not only
does ‘Foetal compartment’ mean amniotic fluid, but also
foetal body. Therefore, the modulation of amniotic me-
diator levels can reflect the action of LF on either the
foetus or the foetal adnexa.
Obviously, amniotic inflammatory and/or coagulation
mediator imbalance can also derive from the mother, es-
pecially in a number of chronic connective tissue diseases
and other genetic conditions. However, knowing that the
trophoblast and the foetus itself do release their own
mediators, in the absence of any maternal disease, their
imbalance should be interpreted as a direct foetal re-
sponsibility. As for the purpose of our study, given the
role of the foetal mediators in the control of maternal
response, it is noteworthy that LF is able to modulate
their balance within the foetal compartment.
The limits of our study were above all the small sam-
ple size which needs to be further increased. Secondly,
the design of the study didn’t allow to establish the best
timing and dosage of LF able to modulate amniotic cyto-
kines to avoid inflammatory complication of pregnancy.
To this purpose, a longitudinal approach would be
useful, although these preliminary data represent a good
starting point to achieve further experimental results.
Conclusions
Overall our data shows that vaginal LF administration
down-regulates 17 AF pro-inflammatory cytokines while
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up-regulating 7 mediators, 5 of which definitively be-
longing to an anti-inflammatory profile. Such a finding
reinforces our earlier assertion on a possible protective
role of this glycoprotein opening to a more extensive
clinical investigation on its use against inflammatory
complications of pregnancy.
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